Iluvien gains marketing authorization in Spain

The Spanish Agency of Medicines and Medical Devices granted Alimera Sciences authorization to market Iluvien in Spain for the treatment of vision impairment associated with chronic diabetic macular edema that is unresponsive to available therapies, according to a news release.The decentralized regulatory procedure for Iluvien (sustained-release fluocinolone acetonide) was completed in the European Union in 2012. The authorization in Spain is the sixth national approval in the EU, following Austria, the United Kingdom, Portugal, France and Germany.

Full Story →